



Press Release

Paris, October 14th

Kurma Partners announces investments in Asceneuron SA and Minoryx Therapeutics SL.

Kurma Partners, a key European player in the financing of Innovation in Healthcare, announces two new investments of Kurma Biofund II, the first Venture Capital fund dedicated to innovations in the rare diseases space.

Asceneuron SA, a Zurich-based biopharmaceutical, announced the closing of a Series A round of CHF 30M (USD 30.6M). The company will use the financing to develop first-in-class small molecules targeting tauopathies such as progressive supranuclear palsy.

Minoryx Therapeutics SL, a Spanish biotech, has raised Series A funding of € 19.4M (USD 21.7M) to reach clinical validation for lead candidate MIN-102 in X-linked Adrenoleukodystrophy, a rare neurodegenerative and life-threatening disease.

About Kurma Partners

Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I and II, Kurma Diagnostics and strategic partnerships with prestigious European research and medical institutions.

www.kurmapartners.com

Press contacts: NewCap - Nicolas Merigeau: +33(0)1 44 71 94 98 – nmerigeau@newcap.fr